{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Near Complete Response (nCR)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Very Good Partial Response (VGPR)"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Minimal Response (MR)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Progressive Disease (PD)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Not Evaluable (NE)"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Unknown"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Disease response and progression were determined using the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC), except for minimal response (MR) and near complete response (nCR) which was based on the European Group for Blood and Marrow Transplantation (EBMT) criteria. Evaluations reported were assessed by the investigator for participants in Phase 2.","groups":[{"description":"The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.","id":"OG000","title":"Phase 2 300 mg 2/7 Schedule"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months","title":"Best Overall Response in Phase 2 as Assessed by Investigator","type":"PRIMARY","unitOfMeasure":"Participants"}